Incretins today: multiple effects and therapeutic potential
Glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) are the incretin hormones initially discovered in the 1960s. GIP and GLP-1 have gained great scientific interest due to their properties in increasing insulin secretion and lowering blood glucose levels. The study of...
Guardado en:
Autores principales: | Oksana V. Tsygankova, Varvara V. Veretyuk, Alexander S. Ametov |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0efa42080d074bf2b56cb951138cb234 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The associations of incretin hormone concentration with gestational diabetes mellitus
por: Tatiana V. Saprina, et al.
Publicado: (2016) -
New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
por: Ekaterina Alekseevna Shestakova
Publicado: (2011) -
Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011) -
Incretin-based therapy: renal effects
por: Anton Ivanovich Korbut, et al.
Publicado: (2016) -
Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
por: Gagik R. Galstyan, et al.
Publicado: (2017)